Compare Royal Bank of Canada (RY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs DENTSPLY SIRONA Inc — how do they compare? Royal Bank of Canada trades at $191.98 (market cap $262.99B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Royal Bank of Canada is far larger — about 152× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| RY | XRAY | |
|---|---|---|
Market Cap | $262.99B | $1.73B |
Volume | 1,016,377 | 6,198,582 |
Sector | Financials | Health |
52-Week High | $217.87 | $14.68 |
52-Week Low | $143.64 | $8.52 |
Typical Hold Time | 47 Days | 72 Days |
Enterprise Value | $730.11B | $3.80B |
Dividend Yield | 2.66% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $191.91, up 0.36% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations, while revenue grew to $66.53B in 2025. Analyst sentiment is mixed with 43% buy ratings, though technical indicators show oversold conditions with RSI at 18.28.
RY presents a value opportunity with reasonable P/E of 17.08 and strong ROE of 17.2%, but faces technical headwinds and stretched valuations in the banking sector. The stock's 32% net margin and dividend yield around 3.7% support income investors, while near-term resistance at $192 may limit upside without fundamental catalysts.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
